CoChat
Sign Up
Cited by 486

Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis

·2009·Advances in Cancer Research
DOI 10.1016/s0065-230x(09)02002-8PMC PMC2933405
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0065-230x(09)02002-8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 269

  1. Ackah E Yu J Zoellner S Iwakiri Y Skurk C Shibata R Ouchi N Easton RM Galasso G Birnbaum MJ Walsh K Sessa WC 2005 Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis J Clin Invest 115 2119 2127 16075056 PMC1180542
  2. Agarwal A Das K Lerner N Sathe S Cicek M Casey G Sizemore N 2005 The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin Oncogene 24 1021 1031 15592509
  3. Amiri KI Richmond A 2005 Role of nuclear factor-kappa B in melanoma Cancer Metastasis Rev 24 301 313 15986139 PMC2668255
  4. Arcaro A Zvelebil MJ Wallasch C Ullrich A Waterfield MD Domin J 2000 Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors Mol Cell Biol 20 3817 3830 10805725 PMC85707
  5. Argiris A Cohen E Karrison T Esparaz B Mauer A Ansari R Wong S Lu Y Pins M Dancey J Vokes E 2006 A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer Cancer Biol Ther 5 766 770 16760642
  6. Atkins MB Hidalgo M Stadler WM Logan TF Dutcher JP Hudes GR Park Y Liou SH Marshall B Boni JP Dukart G Sherman ML 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 909 918 14990647
  7. Autiero M Waltenberger J Communi D Kranz A Moons L Lambrechts D Kroll J Plaisance S De Mol M Bono F Kliche S Fellbrich G 2003 Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 Nat Med 9 936 943 12796773
  8. Awada A Cardoso F Fontaine C Dirix L De Greve J Sotiriou C Steinseifer J Wouters C Tanaka C Zoellner U Tang P Piccart M 2008 The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics Eur J Cancer 44 84 91 18039566
  9. Babaei S Teichert-Kuliszewska K Zhang Q Jones N Dumont DJ Stewart DJ 2003 Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide Am J Pathol 162 1927 1936 12759249 PMC1868142
  10. Backman SA Ghazarian D So K Sanchez O Wagner KU Hennighausen L Suzuki A Tsao MS Chapman WB Stambolic V Mak TW 2004 Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten Proc Natl Acad Sci USA 101 1725 1730 14747659 PMC341836
  11. Bader AG Kang S Vogt PK 2006 Cancer-specific mutations in PIK3CA are oncogenic in vivo Proc Natl Acad Sci USA 103 1475 1479 16432179 PMC1360603
  12. Bailey HH Mahoney MR Ettinger DS Maples WJ Fracasso PM Traynor AM Erlichman C Okuno SH 2006 Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma Cancer 107 2462 2467 17058289
  13. Belaiba RS Bonello S Zahringer C Schmidt S Hess J Kietzmann T Gorlach A 2007 Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells Mol Biol Cell 18 4691 4697 17898080 PMC2096613
  14. Bellacosa A Testa JR Staal SP Tsichlis PN 1991 A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region Science 254 274 277 1833819
  15. Berwick DC Hers I Heesom KJ Moule SK Tavare JM 2002 The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes J Biol Chem 277 33895 33900 12107176
  16. Brabletz T Hlubek F Spaderna S Schmalhofer O Hiendlmeyer E Jung A Kirchner T 2005 Invasion and metastasis in colorectal cancer: Epithelial–mesenchymal transition, mesenchymal–epithelial transition, stem cells and beta-catenin Cells Tissues Organs 179 56 65 15942193
  17. Brachmann SM Yballe CM Innocenti M Deane JA Fruman DA Thomas SM Cantley LC 2005 Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement Mol Cell Biol 25 2593 2606 15767666 PMC1061637
  18. Brazil DP Park J Hemmings BA 2002 PKB binding proteins. Getting in on the Akt Cell 111 293 303 12419241
  19. Brown EB Campbell RB Tsuzuki Y Xu L Carmeliet P Fukumura D Jain RK 2001 In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy Nat Med 7 864 868 11433354
  20. Campbell IG Russell SE Choong DY Montgomery KG Ciavarella ML Hooi CS Cristiano BE Pearson RB Phillips WA 2004 Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 64 7678 7681 15520168
  21. Carmeliet P Jain RK 2000 Angiogenesis in cancer and other diseases Nature 407 249 257 11001068
  22. Carmeliet P Ferreira V Breier G Pollefeyt S Kieckens L Gertsenstein M Fahrig M Vandenhoeck A Harpal K Eberhardt C Declercq C Pawling J 1996 Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele Nature 380 435 439 8602241
  23. Carver DJ Gaston B Deronde K Palmer LA 2007 Akt-mediated activation of HIF-1 in pulmonary vascular endothelial cells by S-nitrosoglutathione Am J Respir Cell Mol Biol 37 255 263 17541013 PMC1994227
  24. Cebe-Suarez S Zehnder-Fjallman A Ballmer-Hofer K 2006 The role of VEGF receptors in angiogenesis; complex partnerships Cell Mol Life Sci 63 601 615 16465447 PMC2773843
  25. Chachami G Simos G Hatziefthimiou A Bonanou S Molyvdas PA Paraskeva E 2004 Cobalt induces hypoxia-inducible factor-1alpha expression in airway smooth muscle cells by a reactive oxygen species- and PI3K-dependent mechanism Am J Respir Cell Mol Biol 31 544 551 15256383
  26. Chaisuparat R Hu J Jham BC Knight ZA Shokat KM Montaner S 2008 Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi’s sarcoma Cancer Res 68 8361 8368 18922908 PMC2645787
  27. Chan TO Rodeck U Chan AM Kimmelman AC Rittenhouse SE Panayotou G Tsichlis PN 2002 Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit Cancer Cell 1 181 191 12086876
  28. Chan S Scheulen ME Johnston S Mross K Cardoso F Dittrich C Eiermann W Hess D Morant R Semiglazov V Borner M Salzberg M 2005 Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer J Clin Oncol 23 5314 5322 15955899
  29. Chandramohan V Jeay S Pianetti S Sonenshein GE 2004 Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels J Immunol 172 5522 5527 15100294
  30. Chang HW Aoki M Fruman D Auger KR Bellacosa A Tsichlis PN Cantley LC Roberts TM Vogt PK 1997 Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase Science 276 1848 1850 9188528
  31. Chang SM Kuhn J Wen P Greenberg H Schiff D Conrad C Fink K Robins HI Cloughesy T De Angelis L Razier J Hess K 2004 Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs Invest New Drugs 22 427 435 15292713
  32. Chang SM Wen P Cloughesy T Greenberg H Schiff D Conrad C Fink K Robins HI De Angelis L Raizer J Hess K Aldape K 2005 Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme Invest New Drugs 23 357 361 16012795
  33. Chee KG Longmate J Quinn DI Chatta G Pinski J Twardowski P Pan CX Cambio A Evans CP Gandara DR Lara PN Jr 2007 The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial Clin Genitourin Cancer 5 433 437 18272025
  34. Chen WS Xu PZ Gottlob K Chen ML Sokol K Shiyanova T Roninson I Weng W Suzuki R Tobe K Kadowaki T Hay N 2001 Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene Genes Dev 15 2203 2208 11544177 PMC312770
  35. Chen J Somanath PR Razorenova O Chen WS Hay N Bornstein P Byzova TV 2005 Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo Nat Med 11 1188 1196 16227992 PMC2277080
  36. Cheng GZ Park S Shu S He L Kong W Zhang W Yuan Z Wang LH Cheng JQ 2008 Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery Curr Cancer Drug Targets 8 2 6 18288938
  37. Cho H Mu J Kim JK Thorvaldsen JL Chu Q Crenshaw EB III Kaestner KH Bartolomei MS Shulman GI Birnbaum MJ 2001a Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta) Science 292 1728 1731 11387480
  38. Cho H Thorvaldsen JL Chu Q Feng F Birnbaum MJ 2001b Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice J Biol Chem 276 38349 38352 11533044
  39. Cho CH Kammerer RA Lee HJ Steinmetz MO Ryu YS Lee SH Yasunaga K Kim KT Kim I Choi HH Kim W Kim SH 2004 COMP-Ang1: A designed angiopoietin-1 variant with nonleaky angiogenic activity Proc Natl Acad Sci USA 101 5547 5552 15060279 PMC397420
  40. Cloughesy TF Yoshimoto K Nghiemphu P Brown K Dang J Zhu S Hsueh T Chen Y Wang W Youngkin D Liau L Martin N 2008 Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med 5 e8 18215105 PMC2211560
  41. Cohen P Frame S 2001 The renaissance of GSK3 Nat Rev Mol Cell Biol 2 769 776 11584304
  42. Contreras V Richardson MA Hao E Keiper BD 2008 Depletion of the cap-associated isoform of translation factor eIF4G induces germline apoptosis in C. elegans Cell Death Differ 15 1232 1242 18451872
  43. Crul M Rosing H de Klerk GJ Dubbelman R Traiser M Reichert S Knebel NG Schellens JH Beijnen JH Bokkel Huinink WW 2002 Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours Eur J Cancer 38 1615 1621 12142051
  44. Cunningham SA Waxham MN Arrate PM Brock TA 1995 Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding J Biol Chem 270 20254 20257 7657594
  45. Dahia PL Marsh DJ Zheng Z Zedenius J Komminoth P Frisk T Wallin G Parsons R Longy M Larsson C Eng C 1997 Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors Cancer Res 57 4710 4713 9354427
  46. Dance M Montagner A Yart A Masri B Audigier Y Perret B Salles JP Raynal P 2006 The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinase J Biol Chem 281 23285 23295 16787925
  47. Davis S Aldrich TH Jones PF Acheson A Compton DL Jain V Ryan TE Bruno J Radziejewski C Maisonpierre PC Yancopoulos GD 1996 Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning Cell 87 1161 1169 8980223
  48. Dayanir V Meyer RD Lashkari K Rahimi N 2001 Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation J Biol Chem 276 17686 17692 11278468
  49. DeBosch B Sambandam N Weinheimer C Courtois M Muslin AJ 2006 Akt2 regulates cardiac metabolism and cardiomyocyte survival J Biol Chem 281 32841 32851 16950770 PMC2724003
  50. Di Cristofano A Pesce B Cordon-Cardo C Pandolfi PP 1998 Pten is essential for embryonic development and tumour suppression Nat Genet 19 348 355 9697695
  51. Diehl JA Cheng M Roussel MF Sherr CJ 1998 Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization Genes Dev 12 3499 3511 9832503 PMC317244
  52. Domin J Waterfield MD 1997 Using structure to define the function of phosphoinositide 3-kinase family members FEBS Lett 410 91 95 9247130
  53. Downward J 1998 Mechanisms and consequences of activation of protein kinase B/Akt Curr Opin Cell Biol 10 262 267 9561851
  54. Duran I Kortmansky J Singh D Hirte H Kocha W Goss G Le L Oza A Nicklee T Ho J Birle D Pond GR 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 1148 1154 17031397 PMC2360568
  55. Easton JB Houghton PJ 2006 mTOR and cancer therapy Oncogene 25 6436 6446 17041628
  56. Emerling BM Weinberg F Liu JL Mak TW Chandel NS 2008 PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Fork-head transcription factor 3a (FOXO3a) Proc Natl Acad Sci USA 105 2622 2627 18268343 PMC2268186
  57. Engelman JA Luo J Cantley LC 2006 The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 606 619 16847462
  58. Faivre S Kroemer G Raymond E 2006 Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov 5 671 688 16883305
  59. Falasca M Maffucci T 2007 Role of class II phosphoinositide 3-kinase in cell signalling Biochem Soc Trans 35 211 214 17371240
  60. Fan QW Knight ZA Goldenberg DD Yu W Mostov KE Stokoe D Shokat KM Weiss WA 2006 A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma Cancer Cell 9 341 349 16697955 PMC2925230
  61. Fang J Xia C Cao Z Zheng JZ Reed E Jiang BH 2005 Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways FASEB J 19 342 353 15746177
  62. Fang J Meng Q Vogt PK Zhang R Jiang BH 2006 A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability J Cell Physiol 209 261 265 16883576
  63. Fang J Ding M Yang L Liu LZ Jiang BH 2007 PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis Cell Signal 19 2487 2497 17826033 PMC2094004
  64. Ferrara N Carver-Moore K Chen H Dowd M Lu L O’Shea KS Powell-Braxton L Hillan KJ Moore MW 1996 Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene Nature 380 439 442 8602242
  65. Folkman J 1995 Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis N Engl J Med 333 1757 1763 7491141
  66. Fosbrink M Niculescu F Rus V Shin ML Rus H 2006 C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1 J Biol Chem 281 19009 19018 16670089
  67. Fouladi M Laningham F Wu J O’Shaughnessy MA Molina K Broniscer A Spunt SL Luckett I Stewart CF Houghton PJ Gilbertson RJ Furman WL 2007 Phase I study of everolimus in pediatric patients with refractory solid tumors J Clin Oncol 25 4806 4812 17947729
  68. Fraser MM Zhu X Kwon CH Uhlmann EJ Gutmann DH Baker SJ 2004 Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo Cancer Res 64 7773 7779 15520182
  69. Fruman DA Snapper SB Yballe CM Davidson L Yu JY Alt FW Cantley LC 1999 Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha Science 283 393 397 9888855
  70. Galanis E Buckner JC Maurer MJ Kreisberg JI Ballman K Boni J Peralba JM Jenkins RB Dakhil SR Morton RF Jaeckle KA Scheithauer BW 2005 Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study J Clin Oncol 23 5294 5304 15998902
  71. Garlich JR De P Dey N Su JD Peng X Miller A Murali R Lu Y Mills GB Kundra V Shu HK Peng Q 2008 A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res 68 206 215 18172313
  72. Geng L Tan J Himmelfarb E Schueneman A Niermann K Brousal J Fu A Cuneo K Kesicki EA Treiberg J Hayflick JS Hallahan DE 2004 A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction Cancer Res 64 4893 4899 15256460
  73. Gerber HP McMurtrey A Kowalski J Yan M Keyt BA Dixit V Ferrara N 1998 Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation J Biol Chem 273 30336 30343 9804796
  74. Gericke A Munson M Ross AH 2006 Regulation of the PTEN phosphatase Gene 374 1 9 16675164
  75. Gills JJ Holbeck S Hollingshead M Hewitt SM Kozikowski AP Dennis PA 2006 Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt Mol Cancer Ther 5 713 722 16546986
  76. Gotze KS Hoffmann D Schatzl HM Peschel C Fend F Decker T 2007 Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells Haematologica 92 1282 1283 17768130
  77. Granville CA Memmott RM Gills JJ Dennis PA 2006 Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway Clin Cancer Res 12 679 689 16467077
  78. Graupera M Guillermet-Guibert J Foukas LC Phng LK Cain RJ Salpekar A Pearce W Meek S Millan J Cutillas PR Smith AJ Ridley AJ 2008 Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration Nature 453 662 666 18449193
  79. Gregory MA Qi Y Hann SR 2003 Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization J Biol Chem 278 51606 51612 14563837
  80. Grille SJ Bellacosa A Upson J Klein-Szanto AJ van Roy F Lee-Kwon W Donowitz M Tsichlis PN Larue L 2003 The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines Cancer Res 63 2172 2178 12727836
  81. Gulati P Gaspers LD Dann SG Joaquin M Nobukuni T Natt F Kozma SC Thomas AP Thomas G 2008 Amino acids activate mTOR complex 1 via Ca2 +/CaM signaling to hVps34 Cell Metab 7 456 465 18460336 PMC2587347
  82. Harima Y Sawada S Nagata K Sougawa M Ostapenko V Ohnishi T 2001 Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy Int J Oncol 18 493 497 11179477
  83. Harrington LS Findlay GM Gray A Tolkacheva T Wigfield S Rebholz H Barnett J Leslie NR Cheng S Shepherd PR Gout I Downes CP 2004 The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins J Cell Biol 166 213 223 15249583 PMC2172316
  84. Hennessy BT Smith DL Ram PT Lu Y Mills GB 2005 Exploiting the PI3K/AKT pathway for cancer drug discovery Nat Rev Drug Discov 4 988 1004 16341064
  85. Hernando E Charytonowicz E Dudas ME Menendez S Matushansky I Mills J Socci ND Behrendt N Ma L Maki RG Pandolfi PP Cordon-Cardo C 2007 The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas Nat Med 13 748 753 17496901
  86. Hettinger K Vikhanskaya F Poh MK Lee MK de BI Zhang JT Reddy SA Sabapathy K 2007 c-Jun promotes cellular survival by suppression of PTEN Cell Death Differ 14 218 229 16676006
  87. Hidalgo M Buckner JC Erlichman C Pollack MS Boni JP Dukart G Marshall B Speicher L Moore L Rowinsky EK 2006 A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer Clin Cancer Res 12 5755 5763 17020981
  88. Horie Y Suzuki A Kataoka E Sasaki T Hamada K Sasaki J Mizuno K Hasegawa G Kishimoto H Iizuka M Naito M Enomoto K 2004 Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas J Clin Invest 113 1774 1783 15199412 PMC420505
  89. Hresko RC Murata H Mueckler M 2003 Phosphoinositide-dependent kinase-2 is a distinct protein kinase enriched in a novel cytoskeletal fraction associated with adipocyte plasma membranes J Biol Chem 278 21615 21622 12682057
  90. Hu P Margolis B Skolnik EY Lammers R Ullrich A Schlessinger J 1992 Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors Mol Cell Biol 12 981 990 1372091 PMC369530
  91. Hu L Hofmann J Jaffe RB 2005 Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma Clin Cancer Res 11 8208 8212 16299254
  92. Huber MA Azoitei N Baumann B Grunert S Sommer A Pehamberger H Kraut N Beug H Wirth T 2004 NF-kappaB is essential for epithelial–mesenchymal transition and metastasis in a model of breast cancer progression J Clin Invest 114 569 581 15314694 PMC503772
  93. Hudes G Carducci M Tomczak P Dutcher J Figlin R Kapoor A Staroslawska E Sosman J McDermott D Bodrogi I Kovacevic Z Lesovoy V 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 17538086
  94. Hurt KJ Musicki B Palese MA Crone JK Becker RE Moriarity JL Snyder SH Burnett AL 2002 Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection Proc Natl Acad Sci USA 99 4061 4066 11904450 PMC122648
  95. Ikenoue T Inoki K Zhao B Guan KL 2008 PTEN acetylation modulates its interaction with PDZ domain Cancer Res 68 6908 6912 18757404
  96. Ispanovic E Haas TL 2006 JNK and PI3K differentially regulate MMP-2 and MT1-MMP mRNA and protein in response to actin cytoskeleton reorganization in endothelial cells Am J Physiol Cell Physiol 291 C579 C588 16672691
  97. Jia S Liu Z Zhang S Liu P Zhang L Lee SH Zhang J Signoretti S Loda M Roberts TM Zhao JJ 2008 Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis Nature 454 776 779 18594509 PMC2750091
  98. Jiang BH Liu LZ 2008 PI3K/PTEN signaling in tumorigenesis and angiogenesis Biochim Biophys Acta 1784 150 158 17964232
  99. Jiang BH Zheng JZ Aoki M Vogt PK 2000 Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells Proc Natl Acad Sci USA 97 1749 1753 10677529 PMC26507
  100. Jiang BH Jiang G Zheng JZ Lu Z Hunter T Vogt PK 2001 Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1 Cell Growth Differ 12 363 369 11457733
  101. Jones N Master Z Jones J Bouchard D Gunji Y Sasaki H Daly R Alitalo K Dumont DJ 1999 Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration J Biol Chem 274 30896 30905 10521483
  102. Jones N Iljin K Dumont DJ Alitalo K 2001 Tie receptors: New modulators of angiogenic and lymphangiogenic responses Nat Rev Mol Cell Biol 2 257 267 11283723
  103. Ju X Katiyar S Wang C Liu M Jiao X Li S Zhou J Turner J Lisanti MP Russell RG Mueller SC Ojeifo J 2007 Akt1 governs breast cancer progression in vivo Proc Natl Acad Sci USA 104 7438 7443 17460049 PMC1863437
  104. Jucker M Sudel K Horn S Sickel M Wegner W Fiedler W Feldman RA 2002 Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin’s lymphoma-derived cell line (CO) Leukemia 16 894 901 11986952
  105. Kaidi A Williams AC Paraskeva C 2007 Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia Nat Cell Biol 9 210 217 17220880
  106. Kanda S Miyata Y Mochizuki Y Matsuyama T Kanetake H 2005 Angiopoietin 1 is mitogenic for cultured endothelial cells Cancer Res 65 6820 6827 16061664
  107. Kapitsinou PP Haase VH 2008 The VHL tumor suppressor and HIF: Insights from genetic studies in mice Cell Death Differ 15 650 659 18219317 PMC3799983
  108. Kim JH Kim B Cai L Choi HJ Ohgi KA Tran C Chen C Chung CH Huber O Rose DW Sawyers CL Rosenfeld MG 2005 Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes Nature 434 921 926 15829968
  109. Kimura T Suzuki A Fujita Y Yomogida K Lomeli H Asada N Ikeuchi M Nagy A Mak TW Nakano T 2003 Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production Development 130 1691 1700 12620992
  110. Knowling M Blackstein M Tozer R Bramwell V Dancey J Dore N Matthews S Eisenhauer E 2006 A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial Invest New Drugs 24 435 439 16528479
  111. Komazawa N Suzuki A Sano S Horie K Matsuura N Mak TW Nakano T Takeda J Kondoh G 2004 Tumorigenesis facilitated by Pten deficiency in the skin: Evidence of p53-Pten complex formation on the initiation phase Cancer Sci 95 639 643 15298725 PMC11159272
  112. Kong D Yamori T 2007 ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms Cancer Sci 98 1638 1642 17711503 PMC11158993
  113. Kuhn JG Chang SM Wen PY Cloughesy TF Greenberg H Schiff D Conrad C Fink KL Robins HI Mehta M DeAngelis L Raizer J 2007 Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma Clin Cancer Res 13 7401 7406 18094423 PMC4918812
  114. Laramee M Chabot C Cloutier M Stenne R Holgado-Madruga M Wong AJ Royal I 2007 The scaffolding adapter Gab1 mediates vascular endothelial growth factor signaling and is required for endothelial cell migration and capillary formation J Biol Chem 282 7758 7769 17178724
  115. Larue L Bellacosa A 2005 Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3′ kinase/AKT pathways Oncogene 24 7443 7454 16288291
  116. Lee KS Kim SR Park SJ Min KH Lee KY Choe YH Park SY Chai OH Zhang X Song CH Lee YC 2008 Mast cells can mediate vascular permeability through regulation of the PI3K-HIF-1alpha-VEGF axis Am J Respir Crit Care Med 178 787 797 18669818
  117. Leighl NB Dent S Clemons M Vandenberg TA Tozer R Warr DG Crump RM Hedley D Pond GR Dancey JE Moore MJ 2008 A Phase 2 study of perifosine in advanced or metastatic breast cancer Breast Cancer Res Treat 108 87 92 17458693
  118. Lelievre E Bourbon PM Duan LJ Nussbaum RL Fong GH 2005 Deficiency in the p110alpha subunit of PI3K results in diminished Tie2 expression and Tie2(−/−)-like vascular defects in mice Blood 105 3935 3938 15687236 PMC1895075
  119. Leslie NR 2006 The redox regulation of PI 3-kinase-dependent signaling Antioxid Redox Signal 8 1765 1774 16987030
  120. Levy AP Levy NS Wegner S Goldberg MA 1995 Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia J Biol Chem 270 13333 13340 7768934
  121. Li J Yen C Liaw D Podsypanina K Bose S Wang SI Puc J Miliaresis C Rodgers L McCombie R Bigner SH Giovanella BC 1997a PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1943 1947 9072974
  122. Li L Ernsting BR Wishart MJ Lohse DL Dixon JE 1997b A family of putative tumor suppressors is structurally and functionally conserved in humans and yeast J Biol Chem 272 29403 29406 9367992
  123. Liaw D Marsh DJ Li J Dahia PL Wang SI Zheng Z Bose S Call KM Tsou HC Peacocke M Eng C Parsons R 1997 Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome Nat Genet 16 64 67 9140396
  124. Lin J Lalani AS Harding TC Gonzalez M Wu WW Luan B Tu GH Koprivnikar K VanRoey MJ He Y Alitalo K Jooss K 2005 Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor Cancer Res 65 6901 6909 16061674
  125. Litman P Ohne O Ben Yaakov S Shemesh-Darvish L Yechezkel T Salitra Y Rubnov S Cohen I Senderowitz H Kidron D Livnah O Levitzki A 2007 A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway Biochemistry 46 4716 4724 17397140
  126. Liu X Rubin JS Kimmel AR 2005 Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins Curr Biol 15 1989 1997 16303557
  127. Liu L Zhu S Gong Z Low BC 2008a K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis PLoS ONE 3 e2850 18682746 PMC2483249
  128. Liu LZ Zheng JZ Wang XR Jiang BH 2008b Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis Cancer Res 68 8183 8188 18829578
  129. Liu X Shi Y Woods KW Hessler P Kroeger P Wilsbacher J Wang J Wang JY Li C Li Q Rosenberg SH Giranda VL 2008c Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression Neoplasia 10 828 837 18670641 PMC2481570
  130. Lu Y Wahl LM 2005 Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway J Leukoc Biol 78 259 265 15800029
  131. Lu Z Ghosh S Wang Z Hunter T 2003 Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion Cancer Cell 4 499 515 14706341
  132. Luo J McMullen JR Sobkiw CL Zhang L Dorfman AL Sherwood MC Logsdon MN Horner JW DePinho RA Izumo S Cantley LC 2005 Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy Mol Cell Biol 25 9491 9502 16227599 PMC1265829
  133. Luo J Sobkiw CL Hirshman MF Logsdon MN Li TQ Goodyear LJ Cantley LC 2006 Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia Cell Metab 3 355 366 16679293
  134. Ma X Ziel-van der Made AC Autar B van der Korput HA Vermeij M van Duijn P Cleutjens KB de Krijger R Krimpenfort P Berns A van der Kwast TH Trapman J 2005 Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis Cancer Res 65 5730 5739 15994948
  135. MacDougall LK Gagou ME Leevers SJ Hafen E Waterfield MD 2004 Targeted expression of the class II phosphoinositide 3-kinase in Drosophila melanogaster reveals lipid kinase-dependent effects on patterning and interactions with receptor signaling pathways Mol Cell Biol 24 796 808 14701751 PMC343800
  136. Maehama T Dixon JE 1998 The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 273 13375 13378 9593664
  137. Maffucci T Piccolo E Cumashi A Iezzi M Riley AM Saiardi A Godage HY Rossi C Broggini M Iacobelli S Potter BV Innocenti P 2005 Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects Cancer Res 65 8339 8349 16166311
  138. Mahimainathan L Das F Venkatesan B Choudhury GG 2006 Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN Diabetes 55 2115 2125 16804083
  139. Maira SM Stauffer F Brueggen J Furet P Schnell C Fritsch C Brachmann S Chene P De Pover A Schoemaker K Fabbro D Gabriel D 2008 Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol Cancer Ther 7 1851 1863 18606717
  140. Maisonpierre PC Suri C Jones PF Bartunkova S Wiegand SJ Radziejewski C Compton D McClain J Aldrich TH Papadopoulos N Daly TJ Davis S 1997 Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 277 55 60 9204896
  141. Makinde T Agrawal DK 2008 Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease J Cell Mol Med 12 810 828 18266978 PMC4401129
  142. Makinen T Jussila L Veikkola T Karpanen T Kettunen MI Pulkkanen KJ Kauppinen R Jackson DG Kubo H Nishikawa S Yla-Herttuala S Alitalo K 2001 Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 Nat Med 7 199 205 11175851
  143. Mandal M Younes M Swan EA Jasser SA Doan D Yigitbasi O McMurphey A Ludwick J El Naggar AK Bucana C Mills GB Myers JN 2006 The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck Oral Oncol 42 430 439 16442835 PMC1414640
  144. Margolin K Longmate J Baratta T Synold T Christensen S Weber J Gajewski T Quirt I Doroshow JH 2005 CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium Cancer 104 1045 1048 16007689
  145. Marone R Cmiljanovic V Giese B Wymann MP 2008 Targeting phosphoinositide 3-kinase: Moving towards therapy Biochim Biophys Acta 1784 159 185 17997386
  146. Marsh DJ Dahia PL Zheng Z Liaw D Parsons R Gorlin RJ Eng C 1997 Germline mutations in PTEN are present in Bannayan-Zonana syndrome Nat Genet 16 333 334 9241266
  147. Marsh RW Rocha Lima CM Levy DE Mitchell EP Rowland KM Jr Benson AB III 2007 A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma Am J Clin Oncol 30 26 31 17278891
  148. Maxwell PH Wiesener MS Chang GW Clifford SC Vaux EC Cockman ME Wykoff CC Pugh CW Maher ER Ratcliffe PJ 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 271 275 10353251
  149. Mayo LD Donner DB 2001 A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus Proc Natl Acad Sci USA 98 11598 11603 11504915 PMC58775
  150. Mazure NM Chen EY Laderoute KR Giaccia AJ 1997 Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element Blood 90 3322 3331 9345014
  151. McGlade CJ Ellis C Reedijk M Anderson D Mbamalu G Reith AD Panayotou G End P Bernstein A Kazlauskas A 1992 SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors Mol Cell Biol 12 991 997 1372092 PMC369531
  152. Meng F Henson R Wehbe-Janek H Ghoshal K Jacob ST Patel T 2007 MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer Gastroenterology 133 647 658 17681183 PMC4285346
  153. Meuillet EJ Ihle N Baker AF Gard JM Stamper C Williams R Coon A Mahadevan D George BL Kirkpatrick L Powis G 2004 In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316 Oncol Res 14 513 527 15559765
  154. Milton DT Riely GJ Azzoli CG Gomez JE Heelan RT Kris MG Krug LM Pao W Pizzo B Rizvi NA Miller VA 2007 Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer Cancer 110 599 605 17577220
  155. Mita MM Mita AC Chu QS Rowinsky EK Fetterly GJ Goldston M Patnaik A Mathews L Ricart AD Mays T Knowles H Rivera VM 2008 Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies J Clin Oncol 26 361 367 18202410
  156. Mizukami Y Fujiki K Duerr EM Gala M Jo WS Zhang X Chung DC 2006 Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc J Biol Chem 281 13957 13963 16543245
  157. Morita Y Manganaro TF Tao XJ Martimbeau S Donahoe PK Tilly JL 1999 Requirement for phosphatidylinositol-3′-kinase in cytokine-mediated germ cell survival during fetal oogenesis in the mouse Endocrinology 140 941 949 9927327
  158. Mottet D Dumont V Deccache Y Demazy C Ninane N Raes M Michiels C 2003 Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells J Biol Chem 278 31277 31285 12764143
  159. Motzer RJ Hudes GR Curti BD McDermott DF Escudier BJ Negrier S Duclos B Moore L O’Toole T Boni JP Dutcher JP 2007 Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma J Clin Oncol 25 3958 3964 17761980
  160. Motzer RJ Escudier B Oudard S Hutson TE Porta C Bracarda S Grunwald V Thompson JA Figlin RA Hollaender N Urbanowitz G Berg WJ 2008 Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 18653228
  161. Murakami M Zheng Y Hirashima M Suda T Morita Y Ooehara J Ema H Fong GH Shibuya M 2008 VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment Arterioscler Thromb Vasc Biol 28 658 664 18174461
  162. Nakao T Shiota M Tatemoto Y Izumi Y Iwao H 2007 Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling J Pharmacol Sci 105 334 341 18057776
  163. Nakatani K Thompson DA Barthel A Sakaue H Liu W Weigel RJ Roth RA 1999 Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen- independent prostate cancer lines J Biol Chem 274 21528 21532 10419456
  164. Naugler WE Karin M 2008 NF-kappaB and cancer-identifying targets and mechanisms Curr Opin Genet Dev 18 19 26 18440219 PMC2587362
  165. Nemenoff RA Simpson PA Furgeson SB Kaplan-Albuquerque N Crossno J Garl PJ Cooper J Weiser-Evans MC 2008 Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha Circ Res 102 1036 1045 18340011
  166. Niu Q Perruzzi C Voskas D Lawler J Dumont DJ Benjamin LE 2004 Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1 Cancer Biol Ther 3 402 405 14739779
  167. O’Donnell A Faivre S Burris HA III Rea D Papadimitrakopoulou V Shand N Lane HA Hazell K Zoellner U Kovarik JM Brock C Jones S 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 1588 1595 18332470
  168. Olsson AK Dimberg A Kreuger J Claesson-Welsh L 2006 VEGF receptor signalling—In control of vascular function Nat Rev Mol Cell Biol 7 359 371 16633338
  169. Onoue T Uchida D Begum NM Tomizuka Y Yoshida H Sato M 2006 Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells Int J Oncol 29 1133 1138 17016644
  170. Orlichenko LS Radisky DC 2008 Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development Clin Exp Metastasis 25 593 600 18286378
  171. Otsu M Hiles I Gout I Fry MJ Ruiz-Larrea F Panayotou G Thompson A Dhand R Hsuan J Totty N Smith AD Morgan SJ 1991 Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase Cell 65 91 104 1707345
  172. Ozes ON Mayo LD Gustin JA Pfeffer SR Pfeffer LM Donner DB 1999 NF-kappaB activation by tumour necrosis factor requires the Akt serine–threonine kinase Nature 401 82 85 10485710
  173. Pandya KJ Dahlberg S Hidalgo M Cohen RB Lee MW Schiller JH Johnson DH 2007 A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: A trial of the Eastern Cooperative Oncology Group (E1500) J Thorac Oncol 2 1036 1041 17975496
  174. Paradiso A Mangia A Azzariti A Tommasi S 2007 Phosphatidylinositol 3-kinase in breast cancer: Where from here? Clin Cancer Res 13 5988 5990 17947458
  175. Patel L Pass I Coxon P Downes CP Smith SA Macphee CH 2001 Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN Curr Biol 11 764 768 11378386
  176. Peralba JM DeGraffenried L Friedrichs W Fulcher L Grunwald V Weiss G Hidalgo M 2003 Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients Clin Cancer Res 9 2887 2892 12912932
  177. Peyssonnaux C Provot S Felder-Schmittbuhl MP Calothy G Eychene A 2000 Induction of postmitotic neuroretina cell proliferation by distinct Ras downstream signaling pathways Mol Cell Biol 20 7068 7079 10982823 PMC86245
  178. Pezzolesi MG Platzer P Waite KA Eng C 2008 Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome Am J Hum Genet 82 1141 1149 18460397 PMC2427229
  179. Philp AJ Campbell IG Leet C Vincan E Rockman SP Whitehead RH Thomas RJ Phillips WA 2001 The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors Cancer Res 61 7426 7429 11606375
  180. Phung TL Ziv K Dabydeen D Eyiah-Mensah G Riveros M Perruzzi C Sun J Monahan-Earley RA Shiojima I Nagy JA Lin MI Walsh K 2006 Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin Cancer Cell 10 159 170 16904613 PMC2531257
  181. Planchon SM Waite KA Eng C 2008 The nuclear affairs of PTEN J Cell Sci 121 249 253 18216329
  182. Podsypanina K Ellenson LH Nemes A Gu J Tamura M Yamada KM Cordon-Cardo C Catoretti G Fisher PE Parsons R 1999 Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems Proc Natl Acad Sci USA 96 1563 1568 9990064 PMC15517
  183. Posadas EM Gulley J Arlen PM Trout A Parnes HL Wright J Lee MJ Chung EJ Trepel JB Sparreboom A Chen C Jones E 2005 A phase II study of perifosine in androgen independent prostate cancer Cancer Biol Ther 4 1133 1137 16138006
  184. Punt CJ Boni J Bruntsch U Peters M Thielert C 2003 Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors Ann Oncol 14 931 937 12796032
  185. Quintero M Brennan PA Thomas GJ Moncada S 2006 Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: Role of free radical formation Cancer Res 66 770 774 16424008
  186. Raymond E Alexandre J Faivre S Vera K Materman E Boni J Leister C Korth-Bradley J Hanauske A Armand JP 2004 Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J Clin Oncol 22 2336 2347 15136596
  187. Reardon DA Quinn JA Vredenburgh JJ Gururangan S Friedman AH Desjardins A Sathornsumetee S Herndon JE Dowell JM McLendon RE Provenzale JM Sampson JH 2006 Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma Clin Cancer Res 12 860 868 16467100
  188. Reddy KB Nabha SM Atanaskova N 2003 Role of MAP kinase in tumor progression and invasion Cancer Metastasis Rev 22 395 403 12884914
  189. Rizell M Andersson M Cahlin C Hafstrom L Olausson M Lindner P 2008 Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer Int J Clin Oncol 13 66 70 18307022
  190. Rizzieri DA Feldman E Dipersio JF Gabrail N Stock W Strair R Rivera VM Albitar M Bedrosian CL Giles FJ 2008 A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 14 2756 2762 18451242
  191. Rodriguez-Viciana P Marte BM Warne PH Downward J 1996 Phosphatidylinositol 3′ kinase: One of the effectors of Ras Philos Trans R Soc Lond B Biol Sci 351 225 231 8650270
  192. Rubinfeld B Albert I Porfiri E Fiol C Munemitsu S Polakis P 1996 Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly Science 272 1023 1026 8638126
  193. Salmena L Carracedo A Pandolfi PP 2008 Tenets of PTEN tumor suppression Cell 133 403 414 18455982
  194. Samuels Y Wang Z Bardelli A Silliman N Ptak J Szabo S Yan H Gazdar A Powell SM Riggins GJ Willson JK Markowitz S 2004 High frequency of mutations of the PIK3CA gene in human cancers Science 304 554 15016963
  195. Sarkaria JN Schwingler P Schild SE Grogan PT Mladek AC Mandrekar SJ Tan AD Kobayashi T Marks RS Kita H Miller RC Limper AH 2007 Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer J Thorac Oncol 2 751 757 17762343
  196. Sasaki T Arai H Beppu T Ogasawara K 2003 Detection of gene amplification and deletion in high-grade gliomas using a genome DNA microarray (GenoSensor Array 300) Brain Tumor Pathol 20 59 63 14756442
  197. Sato TN Tozawa Y Deutsch U Wolburg-Buchholz K Fujiwara Y Gendron-Maguire M Gridley T Wolburg H Risau W Qin Y 1995 Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation Nature 376 70 74 7596437
  198. Schmelzle T Hall MN 2000 TOR, a central controller of cell growth Cell 103 253 262 11057898
  199. Schmidt M Fernandez de Mattos S van der Horst A Klompmaker R Kops GJ Lam EW Burgering BM Medema RH 2002 Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D Mol Cell Biol 22 7842 7852 12391153 PMC134724
  200. Schnell CR Stauffer F Allegrini PR O’Reilly T McSheehy PM Dartois C Stumm M Cozens R Littlewood-Evans A Garcia-Echeverria C Maira SM 2008 Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: Implications for clinical imaging Cancer Res 68 6598 6607 18701483

200 of 269 shown

Cited by

Sorted by citations

Venue
Advances in Cancer Research
Publisher
Elsevier
Published
2009
Pages
19-65
ISSN
0065-230X
DOI
10.1016/s0065-230x(09)02002-8
PMC
PMC2933405
Cited by
486
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review